Zoetis Stock Drops 3.56% Despite Earnings and Revenue Beats, Trading Above Average Volume

Market Snapshot

On March 18, 2026, Zoetis (ZTS) closed at $117.35, reflecting a 3.56% decline from its previous close of $121.68. The stock traded within a day’s range of $116.88 to $120.78, with a volume of 5.12 million shares, above its average volume of 4.51 million. Despite outperforming its 52-week low of $114.47, the stock remained well below its 52-week high of $172.23. The price drop occurred despite Zoetis reporting Q4 2025 earnings of $1.48 per share, exceeding forecasts by 5.71%, and revenue of $2.4 billion, 1.69% above expectations.

Key Drivers

Zoetis’ 3.56% decline on March 18, 2026, reflects a mix of strong earnings performance, competitive pressures, and market sentiment shifts. While the company exceeded Q4 2025 earnings and revenue forecasts, the stock fell 1.96% in pre-market trading following a 6% drop in the prior session. This volatility suggests investor skepticism about near-term growth prospects, particularly in light of competitive challenges in parasiticide and dermatology markets.

The company’s full-year 2025 results showed resilience, with revenue reaching $9.5 billion (+2% YoY) and adjusted net income of $2.8 billion (+6% YoY), driven by the Simparica franchise and diagnostics. However, investors appeared to discount these gains, as the stock’s decline outpaced the magnitude of earnings surprises. Zoetis returned $3.2 billion to shareholders in 2025, including a 15.2% year-over-year dividend increase, yet the forward dividend yield of 1.74% did not offset concerns about margin pressures.

A key factor in the stock’s underperformance was the broader market context. The 5.71% EPS surprise and 1.69% revenue surprise occurred amid a 6% prior-session drop, indicating broader market jitters. Additionally, while Zoetis projects 3-5% organic revenue growth and 3-6% adjusted net income growth for 2026, these targets may be perceived as conservative compared to historical performance. For instance, Q4 2025 operating income of $798 million reflected a 4.3% year-over-year decline, and full-year 2024 operating income fell 10.8% despite revenue growth of 2.9%.

Strategic initiatives, such as the 2026 launch of Lenivia in the EU and Canada, and anticipated FDA approval in 2027, may not materialize for several years. Competitors in parasiticide and dermatology markets have also intensified pressure, with Zoetis acknowledging these challenges in its guidance. Meanwhile, R&D expenses, while stable at $1.5-1.8 billion annually, did not translate into near-term revenue drivers.

The stock’s price-to-earnings ratio of 19.49 (TTM) and a beta of 0.95 suggest investors are pricing in moderate growth and lower volatility than the broader market. However, the 3.56% drop indicates a reassessment of these fundamentals, possibly due to macroeconomic concerns or sector-specific risks. Zoetis’ trailing 12-month EPS of $6.02 and a 12-month target estimate of $151.00 imply a potential 30% upside, but the recent selloff highlights lingering doubts about execution risks and market share dynamics.

In summary, Zoetis’ March 18 decline reflects a confluence of strong earnings juxtaposed with investor caution about competitive threats, margin pressures, and macroeconomic uncertainty. While the company’s pipeline and shareholder returns remain strengths, near-term execution and market conditions will likely dictate whether these fundamentals translate into sustained stock performance.